upadacitinib phase 2 ulcerative colitis

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
upadacitinib phase 2 ulcerative colitis	0.06	0.5	9291	19	39
upadacitinib	1.41	0.6	8413	31	12
phase	1.87	0.8	2171	51	5
2	1.32	0.3	6272	56	1
ulcerative	1.76	0.6	9977	80	10
colitis	0.22	0.6	5754	48	7

Keyword	CPC	PCC	Volume	Score
upadacitinib phase 2 ulcerative colitis	0.62	0.3	2745	55
upadacitinib for ulcerative colitis	0.16	0.4	4655	12
upadacitinib ulcerative colitis approval	0.89	0.4	2783	84
upadacitinib pediatric ulcerative colitis	1.07	0.6	4330	57
ipt upadacitinib colitis ulcerosa	1.27	0.7	4570	28
upadacitinib crohn's and colitis uk	1.76	0.6	7752	55
upadacitinib zulassung colitis ulcerosa	1.27	0.9	4809	40
upadacitinib phase 3 crohn's disease	0.82	0.1	5037	82
tofacitinib acute severe ulcerative colitis	1.87	0.5	1620	92
tofacitinib ulcerative colitis guidelines	0.34	0.8	2363	33
adalimumab ulcerative colitis phase 3	0.89	0.3	6247	75
tofacitinib in ulcerative colitis	0.24	0.7	3799	83
ulcerative colitis guideline 2022	1.53	0.4	9524	30
ulcerative colitis treatment guidelines 2022	1.42	0.8	6307	45
upadacitinib dose for crohn's	0.33	0.4	5338	66
new treatment for ulcerative colitis 2022	0.41	0.5	3879	55
tofacitinib pediatric ulcerative colitis	0.72	0.7	481	1
upadacitinib patient information leaflet	0.24	1	9205	93
upadacitinib up to date	0.47	0.9	1035	9
upadacitinib phase 3 ulcerative colitis	1.63	0.5	6535	82
fda approval ulcerative colitis	0.2	0.6	1642	38
upadacitinib fda approval history	1.43	0.3	8266	4
for upadacitinib is prescription required	1.25	0.9	2470	96
upadacitinib atopic dermatitis approval	1.2	0.8	9755	11
fda approved drugs for ulcerative colitis	0.73	0.4	7506	96
upadacitinib atopic dermatitis fda approval	1.17	0.6	9037	60
upadacitinib extended-release tablets	0.62	0.8	812	51
drugs approved for ulcerative colitis	1.85	0.6	893	15